Clinical Trial Detail

NCT ID NCT03499899
Title A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

triple-receptor negative breast cancer

Therapies

Carboplatin + LAG525

Carboplatin + LAG525 + Spartalizumab

LAG525 + Spartalizumab

Age Groups: adult senior

No variant requirements are available.